The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults

Coming Soon.

Year: 2022

Reference: Aljumaah, M. R., Bhatia, U., Roach, J., Gunstad, J., & Azcarate Peril, M. A. (2022). The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults. Clinical nutrition (Edinburgh, Scotland), 41(11), 2565–2576. https://doi.org/10.1016/j.clnu.2022.09.012

Related Studies

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications

Irritable bowel syndrome (IBS) symptoms have been effectively reduced by treatments that target the gut-brain axis (GBA). People with inflammatory bowel disease (IBD) have much higher rates of common mental illnesses and symptoms similar to IBS, which may indicate that the GBA plays a part in this illness. Manipulating the gut-brain axis could provide new […]

The gut microbiota-immune-brain axis: Therapeutic implications

Role of the Microbiota-Gut-Brain Axis in Human Health Human health is greatly impacted by the microbiota-gut-brain axis, which affects behavior, brain activity, and gastrointestinal function. A key communication pathway within this axis is the immune system, which connects the gut microbiome to neuroinflammatory processes in both health and disease. Findings from Recent Review on Gut-Brain-Immune […]